Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: A pilot study

C. Lhommé, PH Brault, J. H. Bourhis, P. Pautier, N. Dohollou, P. Y. Dietrich, G. Akbar-Zadeh, C. Lucas, J. L. Pico, M. Hayat

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    20 Citations (Scopus)

    Résumé

    Vaginal bleeding during aplasia can induce transfusion support, infection and discomfort. Oral and intramuscular hormonotherapy can be toxic and/or difficult to manage (mucositis). This single-center pilot study evaluated the efficacy and safety of leuprorelin (L) in preventing heavy vaginal bleeding in 20 nonmenopausal women with leukemia, lymphoma or myeloma and foreseable therapy-induced thrombocytopenia. Until platelet recovery, patients received subcutaneous injections of L, with concomitant nomegestrol acetate (NA) during the first 35 days to prevent flare-up. Median age was 33 years (18 - 48). Platelet nadir was <20 × 109/l in 17 patients; 103 L injections were performed (median per patient : 4 [1 - 14]). No moderate or severe adverse event was related to hormonal therapy. Seventeen patients did not experience any clinically or therapeutically relevant bleeding. Eleven spottings and 8 metrorrhagias (mean duration : 3 days) occurred in 11 patients, requiring enhanced NA in 3 cases (baseline platelet count was < 20 × 109/l in 1 pt, premature termination of NA [the single platelet transfusion for metrorrhagia] in 1 pt, and endometrial hyperplasia (EH) in the third). In patients without EH, only 5 spottings were observed after the third injection, without neither clinical nor therapeutic impact (63 injections). In conclusion, leuprorelin administration is safe and effective in preventing vaginal bleeding. The sustained-release form and subcutaneous administration offer quality of life advantages.

    langue originaleAnglais
    Pages (de - à)1033-1041
    Nombre de pages9
    journalLeukemia and Lymphoma
    Volume42
    Numéro de publication5
    Les DOIs
    étatPublié - 1 janv. 2001

    Contient cette citation